Finally, there is still a potential to improve the therapeutic activity of PD-1/PD-L1 blockade in B-cell malignancies and DLBCL by exploring the utility of novel combinational immunotherapy strategies, as well as by considering these therapies in a selected subset of patients with higher PD-L1 levels. Here, CD274 is linked to diffuse large B-cell lymphoma.